Publicaciones en colaboración con investigadores/as de National Cancer Center Hospital (60)

2024

  1. Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial

    Lung Cancer, Vol. 189

  2. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

    The Lancet Oncology

2023

  1. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

    JTO Clinical and Research Reports, Vol. 4, Núm. 1

  2. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

    Annals of Oncology

  3. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 8, pp. 925-935

  4. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

    Cancers, Vol. 15, Núm. 16

  5. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

    The Lancet, Vol. 402, Núm. 10395, pp. 41-53

  6. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 35, pp. 5363-5375

  7. Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.

    Journal of Clinical Oncology

  8. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

    Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185

  9. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer

    Cancer Science, Vol. 114, Núm. 3, pp. 1026-1036

  10. Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

    New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2063-2075

  11. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2893-2903

2022

  1. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

    Annals of Oncology, Vol. 33, Núm. 5, pp. 466-487

  2. Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

    British Journal of Clinical Pharmacology, Vol. 88, Núm. 7, pp. 3182-3192

  3. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Journal of Thoracic Oncology, Vol. 17, Núm. 2, pp. 289-308

  4. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer

    Future oncology (London, England), Vol. 18, Núm. 28, pp. 3133-3141

  5. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 23, Núm. 3, pp. 393-405

  6. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

    The Lancet Oncology, Vol. 23, Núm. 5, pp. 659-670

  7. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

    The Lancet Oncology, Vol. 23, Núm. 10, pp. 1274-1286